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Abstract
Background: Infectious complications are the major cause of death in acute pancreatitis. Small
bowel bacterial overgrowth and subsequent bacterial translocation are held responsible for the
vast majority of these infections. Goal of this study is to determine whether selected probiotics are
capable of preventing infectious complications without the disadvantages of antibiotic prophylaxis;
antibiotic resistance and fungal overgrowth.
Methods/design: PROPATRIA is a double-blind, placebo-controlled randomised multicenter trial
in which 200 patients will be randomly allocated to a multispecies probiotic preparation (Ecologic
641) or placebo. The study is performed in all 8 Dutch University Hospitals and 7 non-University
hospitals. The study-product is administered twice daily through a nasojejunal tube for 28 days or
until discharge. Patients eligible for randomisation are adult patients with a first onset of predicted
severe acute pancreatitis: Imrie criteria 3 or more, CRP 150 mg/L or more, APACHE II score 8 or
more. Exclusion criteria are post-ERCP pancreatitis, malignancy, infection/sepsis caused by a
second disease, intra-operative diagnosis of pancreatitis and use of probiotics during the study.
Administration of the study product is started within 72 hours after onset of abdominal pain. The
primary endpoint is the total number of infectious complications. Secondary endpoints are
mortality, necrosectomy, antibiotic resistance, hospital stay and adverse events. To demonstrate
that probiotic prophylaxis reduces the proportion of patients with infectious complications from
50% to 30%, with alpha 0,05 and power 80%, a total sample size of 200 patients was calculated.
Conclusion: The PROPATRIA study is aimed to show a reduction in infectious complications due
to early enteral use of multispecies probiotics in severe acute pancreatitis.
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Background
Infection of pancreatic necrosis is the major cause of death
in acute pancreatitis [1-4] Small bowel bacterial over-
growth and subsequent bacterial translocation are held
responsible for the majority of these infections [5-9] Anti-
biotic prophylaxis has been studied in several trials [10-
13]. Recently, a well-designed placebo-controlled trial
failed to show a reduction of infectious complications
[14]. A multicenter trial from the Netherlands, using top-
ical and enteral antibiotics to reduce bacterial overgrowth
(selective bowel decontamination, SBD) showed a reduc-
tion in infected necrosis [15]. Despite favourable results,
SBD has not been widely implemented due to the work-
load associated with it and the reluctance to use antibiot-
ics for a long period of time with risks of bacterial
resistance and fungal infection [16,17]. Microbial antibi-
otic resistance has become a worldwide problem due to
excessive use. The World Health Organisation has advo-
cated the use of microbial interference therapy: non-path-
ogens (probiotics) to restrain pathogens [18]. It is the goal
of the present study to investigate the use of prophylactic
probiotics as an alternative strategy.
Several trials with enteral probiotics have shown a signifi-
cant reduction of infectious complications both in acute
pancreatitis and in patients undergoing major abdominal
surgery [19-21] A well-designed placebo-controlled trial
with Lactobacillus plantarum in patients with acute pancre-
atitis showed very interesting results: a significant reduc-
tion of infected pancreatic necrosis (1/22 versus 7/23
infected necrosis)[19]. However, some criticised this
study because of the exclusion of biliary pancreatitis
patients and some statistical flaws [22,23]. In these and
other trials a single probiotic strain was used.
It has been suggested that multispecies probiotics are
more effective, because effects are strain specific. Combi-
nations of probiotics can be designed so that strain-spe-
cific properties are additive or synergistic. Based on in vitro
data, a selection of 6 out of 75 probiotic strains was made
by Winclove Bio Industries (Amsterdam, the Netherlands)
in co-operation with the Departments of Paediatric
Immunology and Surgery, of the UMC Utrecht (Utrecht,
The Netherlands). This paper describes the rationale of
this product and the design of the study.
Rationale for the efficacy of multispecies probiotics in 
acute pancreatitis
The bacteria responsible for infection of (peri-)pancreatic
necrosis most often originate from the gut [2,5,27] The
pathophysiology of infection of peri-pancreatic necrosis
and the steps amenable to therapeutic intervention are
essentially unknown. Upper gastrointestinal dysmotility
(UGID) has been observed in acute pancreatitis (AP) as
well as in cholestasis and sepsis [6-8] UGID may lead to
small bowel bacterial overgrowth (SBBO)[6]. In immuno-
compromised patients this bacterial overgrowth may lead
to bacterial translocation (BT) [5,6] BT is not only held
responsible for infectious complications, but it also con-
tributes to the overproduction of pro-inflammatory
cytokines during acute necrotising pancreatitis (ANP)
[28]. These cytokines are key factors in the pathogenesis of
multi-organ failure and sepsis.
Prevention of UGID, SBBO and BT may lead to prevention
of infected pancreatic necrosis and the resulting systemic
complications. Intravenous antibiotic prophylaxis is con-
sidered an option to prevent pancreatic infection, but
results from randomised clinical trials are conflicting [10-
14].
Probiotics are living micro-organisms that upon oral
delivery exert a range of health promoting properties. For
a growing number of inflammatory diseases (gastrointes-
tinal, airway or skin) probiotics are being used, with vari-
able clinical outcome. It is hypothesised that probiotics
have an effect on different levels. We developed a multi-
species probiotic preparation that aims to prevent SBBO
and BT in ANP through (1) stimulation of the production
of anti-inflammatory cytokines, especially interleukin-10,
at the level of the intestinal mucosa[29], (2) stimulation
of gastrointestinal motility[30] and (3) competitive inhi-
bition of opportunistic pathogens[31]. The individual
strains each have their own capacity to inhibit growth of
specific potential pathogenic micro-organisms (PMO's),
as for instance Escherichia Coli or Enterococcus species. The
combination of these probiotics, in vitro, inhibits the
growth of all relevant PMO's known to infect pancreatic
necrosis [31].
Methods / design
Study objectives
The study objective is to show that probiotics are effective
in reducing the number of infectious complications dur-
ing the course of acute pancreatitis.
Primary endpoint
The primary endpoint is the total numbers of infectious
complications during the hospital stay for acute pancrea-
titis, see table 1.
Secondary endpoints
Secondary endpoints are mortality, necrosectomy, use of
antibiotics, total hospital stay, intensive care stay, side
effects, abdominal complaints by a patient visual ana-
logue scale questionnaire, sequential organ failure assess-
ment (SOFA) scores, bacterial resistance and total costs.BMC Surgery 2004, 4:12 http://www.biomedcentral.com/1471-2482/4/12
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Design
PROPATRIA is a double-blind, placebo-controlled ran-
domised multicenter trial. The randomisation is stratified
according to the aetiology of the acute pancreatitis (ie. bil-
iary versus non-biliary), also block-randomisation per
hospital is used. Its design and timing of the investiga-
tions are presented in Figure 1 and Table 2, respectively.
Setting
Patients will be enrolled from all 8 Dutch University Hos-
pitals and 7 non-University hospitals.
Patients
A total of 200 adult patients with a first episode of pre-
dicted severe acute pancreatitis will be randomised.
Eligibility criteria
Inclusion Criteria
• age equal to or above 18 years
• first episode of acute pancreatitis
• written and oral informed consent
Exclusion criteria • post-ERCP pancreatitis
PROPATRIA according to CONSORT Figure 1
PROPATRIA according to CONSORT.
To be assessed for 
eligibility (n=500) 
To be randomised 
(n=200) 
Not meeting randomisation 
criteria (n=240)  
Refusal to participate (n=30) 
Other reasons (n=30) 
To be allocated to intervention (n=100)  
 - Receive allocated intervention (n=96) 
 - Not receive allocated intervention (n=4)
To be analysed  (n=94)  To be analysed  (n=94) 
To be lost to follow up (n=2) 
To be allocated to intervention (n=100)  
 - Receive allocated intervention (n=96) 
 - Not receive allocated intervention (n=4)
To be lost to follow up (n=2) BMC Surgery 2004, 4:12 http://www.biomedcentral.com/1471-2482/4/12
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• malignancy
• infection/sepsis caused by a second disease
• intra-operative diagnosis
• immunocompromised patients
• use of probiotics during admission
Randomisation criteria
After inclusion in the study, patients with predicted severe
acute pancreatitis, represented by at least one of the fol-
lowing scores: 3 Imrie criteria, CRP 150 mg/L, APACHE II
score 8, are randomised within the first 72 hours after the
onset of abdominal pain. Patients with a predicted mild
attack of acute pancreatitis do not receive the study prod-
uct. They do give informed consent and are monitored.
Ethics, informed consent
This study is conducted in accordance with the principles
of the Declaration of Helsinki and 'good clinical practice'
guidelines. The independent ethics committee of all 15
participating hospitals approved the final protocol. Oral
and written informed consent in form is obtained from
the patient before inclusion in the trial.
Safety
All the probiotics used in this study have a long history of
use in the food industry. Probiotics have been studied in
many critical ill and immunocompromised patients with-
out any serious adverse events being noted. There is one
trial that studied probiotics in acute pancreatitis patients
and no serious advents were noted. If an infection with
one of the administered probiotics might occur, this could
be treated with antibiotics. During administration of the
study-product both the patient and the nursing staff are
asked to register any potential side effect or adverse event.
An independent monitoring committees will discuss all
reported (serious) adverse events.
Statistical analysis
Intention- to-treat
The analysis will be performed on the basis of an inten-
tion-to-treat (ITT) population and with respect to ITT
principles. Also a per-protocol analysis and an analysis for
necrotising versus non-necrotising pancreatitis will be
performed.
Interim-analysis
For ethical reasons it is desirable to end a therapeutic
experiment once a statistical significant difference in treat-
ment results has been reached. This study uses the stop-
ping-rules according to Snapinn [32]. An interim-analysis
will be performed after the data of the first 100 patients
(50% fraction) is obtained. According to Snappin, the
trial will be ended at this interim-analysis at p < 0,0081.
The study will also be ended in case of adverse events
without possibility of positive outcome, p > 0,382. The
monitoring committee will discuss the results of the
interim-analysis and advice the steering committee. The
steering committee decides on the continuation of the
trial.
Sample size
It is anticipated that probiotics will lead to a reduction of
infectious complications from 50% (% of patients) to
30%. The sample size calculation is based on α = 0.05,
and a power of 80% This leads to a required sample size
of 188 patients. Taking into account a 5% loss-to-follow
up, a total of 2 × 100 patients will be randomised. Based
on hospital data of 2002 about 500 patients have to be
included in order to randomise 200 patients with pre-
dicted severe acute pancreatitis. There is one post-dis-
charge follow-up after three months. The expected study
end is in 2006 (2 years inclusion period).
Randomisation
The randomisation list was generated by using the website
Randomization.com http://www.randomization.com.
According to this list a stratified random allocation of
probiotics and placebo was performed. Each participating
hospital received a series of subsequently numbered iden-
Table 1: Infectious complications
Complication Definition
Bacterial infection body temperature > 38 degrees and increased number of neutrophils and CRP in peripheral blood 
and one of the below:
Infected pancreatic necrosis Positive fine needle aspiration culture or air bubbles in the pancreatic necrosis on CT-scan.
Pneumonia Coughing, dyspnoea, radiography with infiltrative abnormalities, lowered arterial bloodgass. On the 
intensive care unit a positive endotracheal culture is mandatory.
Urinary tract infection Dysuria with bacteraemia (>10.000 CFU/mL)BMC Surgery 2004, 4:12 http://www.biomedcentral.com/1471-2482/4/12
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tical containers with probiotics or placebo. Patients with
biliary cause of the pancreatitis are allocated to the lowest
possible number available whereas patients with non-bil-
iary cause are allocated to the highest possible number
available (stratification).
Blinding
Both the probiotics and placebo are packed in identical,
numbered sachets. These sachets are packed in identical,
numbered containers. The probiotics and placebo are
identical in weight, colour, smell and taste. All doctors,
nurses, research staff and patients involved are unaware of
the treatment administered to the patient.
Treatment program
Patients eligible for inclusion are followed during 72
hours after onset of the abdominal pain. When a patient
meets a randomisation criteria (preferably within 24
hours), a nasojejunal feeding tube is passed and adminis-
tration of the study product (Ecologic® 641, Winclove Bio
Industries, Amsterdam, The Netherlands) and fibre
enriched tube feeding (Multifibre®, Nutricia, Zoetermeer,
The Netherlands) is started. Ecologic® 641 consists of 6
strains of viable and freeze-dried bacteria, namely 4 lacto-
bacilli: Lactobacillus acidophilus, Lactobacillus casei, Lactoba-
cillus salivarius, Lactococcus lactis, and 2 bifidobacteria:
Bifidobacterium bifidum and Bifidobacterium lactis in a total
daily dose of 1010 bacteria. The study-product is adminis-
tered twice daily through a nasojejunal tube for a maxi-
mum of 28 days. The treatment is stopped when a patient
is diagnosed with infected pancreatic necrosis, is dis-
charged or dies. A standard protocol for the treatment of
acute pancreatitis is followed. During ERC with sphincter-
otomy in case of biliary pancreatitis antibiotic prophylaxis
is allowed. Prophylactic use of proton pump inhibitors is
only allowed in case of a clinical history of peptic diseases
like peptic ulcer disease and reflux esophagitis. Prophylac-
tic use of antibiotics is not allowed. At 7–10 days after
admission, a routine CT scan is performed to detect pan-
creatic necrosis. Fine needle aspiration in (peri)pancreatic
collections is performed only in case of clinical suspicion
of infected necrosis. Further culturing, imaging and treat-
ment are all based on clinical findings.
Monitoring
A research nurse monitors the participating centres and
patients. Every 6 months all centres are visited by a second
independent research nurse who checks, at least, 10% of
every patient's data.
Follow-up
Patients are followed during their hospital stay. There is
one follow-up visit, 3 months after discharge, including
an abdominal ultrasound and a short questionnaire
regarding abdominal pain and daily activities.
Discussion
Only patients with predicted severe acute pancreatitis are
randomised. Patients with mild acute pancreatitis are con-
sidered not eligible for randomisation because of their
low risk to develop infectious complications. If such
patients would be included, a very large number of
patients would be needed to demonstrate a significant
effect between the treated and the non-treated patients. To
properly introduce the concept and potential of probiotic
prophylaxis, the use of prophylactic antibiotics was dis-
cussed during the preparations of the study. About 30% of
the hospitals participating in the study commonly used
prophylactic antibiotics, once a patient was diagnosed
with pancreatic necrosis. Because of the lack of evidence it
was decided, even before the results of the most recent
German trial[14] were presented, not to administer pro-
phylactic antibiotics in case of pancreatic necrosis without
clinical suspicion of infected necrosis. When patients do
receive antibiotics, for instance because of an urinary tract
infection, effort is made to administer the study product
with a 4-hour interval in order to minimise interference of
the antibiotics with the probiotics.
The maximum of 72 hours between onset of symptoms
and start of treatment was decided upon, based on the
consideration that probiotics are expected to prevent
infection of pancreatic necrosis. Therefore the probiotics
should be administered prior to the stage that bacterial
overgrowth starts and intraluminal bacteria migrate across
the mucosal barrier. Experimental studies have shown
that bacterial overgrowth occurs very early, within 24
hours after onset, in the course of acute pancreatitis and
reduction of the bacterial load in the proximal small
bowel by intraluminal antibiotics reduces the risk of infec-
tion of pancreatic necrosis [8,33,34].
The presence of pancreatic necrosis can only be detected
reliably 5–7 days after onset [35]. This is too late to effec-
tively prevent bacterial overgrowth and translocation and
therefore "predictive laboratory scores" are used as ran-
domisation criteria and not diagnosis of pancreatic necro-
sis on CT scan. The scoring systems used are also simple
and generally available. A major disadvantage though, is
the limited positive predictive value and the high number
of false positives [36,37]. During interim-analysis the
number of false positives will be calculated and the sam-
ple size may be adjusted.
All randomised patients will receive early enteral feeding
by a jejunal feeding tube. Since patients with predicted
severe pancreatitis would develop severe pancreatitis in
only 50% of the cases, the fraction with a mild course
would normally not receive a nasojejunal feeding tube. It
is unavoidable to prevent this over treatment for patients
with a mild course because the current scoring systems failBMC Surgery 2004, 4:12 http://www.biomedcentral.com/1471-2482/4/12
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to select all patients with a severe course and early inter-
vention is warranted.
The primary outcome parameter 'total of infectious com-
plications', was chosen because it was shown in previous
trials that also the number of pulmonary and urinary tract
infections can be reduced by probiotics [19-21] This fits in
with the concept that such complications are secondary to
bacterial translocation.
All of the infectious complications are documented in the
study period until the patient reaches one of the study-
endpoints: infected necrosis, discharge or in-hospital
death.
Conclusion
PROPATRIA is a double-blind, placebo-controlled ran-
domised multicenter trial that aims to show a reduction in
infectious complications by the enteral use of a multispe-
cies probiotics preparation in patients with predicted
severe acute pancreatitis.
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CRP c-reactive protein
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tion II
ERC endoscopic retrograde cholangiography
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Table 2: Study Flowchart
Visit Admission Day 2 Day 5 Day 10 Day 14 Day 21 Day 28 Day 35 Discharge 3 months
Informed consent X
Clinical scores XXXXXXX XX
US# X X
CT* X
L a b o r a t o r y XXXXXXX X
Study product X§ X§ XXXXX
# US = abdominal ultrasound to detect gallstones (at admission) or pseudocyste (at follow-up)
* CT = abdominal computer tomographic scan to detect (peri-)pancreatic necrosis
§ = Within 72 hours after onset of pain the administration of the study product is started.BMC Surgery 2004, 4:12 http://www.biomedcentral.com/1471-2482/4/12
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